Roche Proposes Ex-Takeda CEO Christophe Weber for Board Seat at 2027 AGM

Roche (RHHBY) said its Board of Directors approved a proposal to nominate Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to its Board at the Annual General Meeting scheduled for March 9, 2027. Weber led Takeda from 2014 until 2025, overseeing its $62 billion acquisition of Shire and expanding the Japanese drugmaker's global oncology and rare disease portfolio. The nomination signals Roche's push to add large-scale M&A and international pharmaceutical leadership experience to its board as the Swiss company navigates patent expirations and pipeline pressure. Shareholders will vote on the appointment at the 2027 AGM.